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ARTICLE
Identiﬁcation of Genetic Variants Contributing
to Cisplatin-Induced Cytotoxicity by Use
of a Genomewide Approach
R. Stephanie Huang,* Shiwei Duan,* Sunita J. Shukla, Emily O. Kistner, Tyson A. Clark,
Tina X. Chen, Anthony C. Schweitzer, John E. Blume, and M. Eileen Dolan
Cisplatin, a platinating agent commonly used to treat several cancers, is associated with nephrotoxicity, neurotoxicity,
and ototoxicity, which has hindered its utility. To gain a better understanding of the genetic variants associated with
cisplatin-induced toxicity, we present a stepwise approach integrating genotypes, gene expression, and sensitivity of
HapMap cell lines to cisplatin. Cell lines derived from 30 trios of European descent (CEU) and 30 trios of African descent
(YRI) were used to develop a preclinical model to identify genetic variants and gene expression that contribute to cisplatin-
induced cytotoxicity in two different populations. Cytotoxicity was determined as cell-growth inhibition at increasing
concentrations of cisplatin for 48 h. Gene expression in 176 HapMap cell lines (87 CEU and 89 YRI) was determined
using the Affymetrix GeneChip Human Exon 1.0 ST Array. We identiﬁed six, two, and nine representative SNPs that
contribute to cisplatin-induced cytotoxicity through their effects on 8, 2, and 16 gene expressions in the combined,
Centre d’Etude du Polymorphisme Humain (CEPH), and Yoruban populations, respectively. These genetic variants con-
tribute to 27%, 29%, and 45% of the overall variation in cell sensitivity to cisplatin in the combined, CEPH, and Yoruban
populations, respectively. Our whole-genome approach can be used to elucidate the expression of quantitative trait loci
contributing to a wide range of cellular phenotypes.
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Cisplatin, a platinating agent, is commonly used to treat
head and neck, testicular, lung, and gynecological can-
cers.1–3 It has been shown that cisplatin exerts its antitu-
mor activity by binding preferentially to the nucleophillic
positions on guanine and adenine of DNA, resulting in
the formation of intra- and interstrand crosslinks. Even-
tually, crosslinks lead to DNA-strand breaks and, ulti-
mately, to cell death.4,5 Despite its wide usage, dose-limi-
ting toxicities—in particular, nephrotoxicity6 and neuro-
toxicity7—have hindered the utility of this agent. In ad-
dition, treatment-induced ototoxicity can result in dose
reduction or discontinuation of cisplatin treatment.8 The
incidences of cisplatin treatment–induced toxicities are
highly variable and are associated with cumulative treat-
ments or dose intensities.7
High levels of drug efﬂux transporters, detoxiﬁers, and
DNA-repair proteins and a low Bax:Bcl-2 ratio have all
been suggested to play a role in cisplatin resistance.9 Ge-
netic variants in candidate genes have demonstrated an
association with clinical response to or toxicity from cis-
platin. For example, two common SNPs of ERCC1 are cor-
related with an increased risk of toxicity and with the
survival of cisplatin-treated patients with non–small-cell
lung cancer.10,11 Polymorphisms in cytokine-promoter
genes (e.g., TNF, IL1, IL6) have been suggested to be as-
sociated with toxicities induced by treatment with 5-ﬂuo-
rouracil and cisplatin.12 Glutathione S-transferase genetic
polymorphisms have also been associated with treatment
outcomes of paclitaxel- and cisplatin-based chemother-
apy.13 An illustration of candidate genes involved in the
mechanism of cisplatin activity can be found at the
PharmGKB Web site. Although the study of candidate
genes and pathways has increased our understanding of
the mechanism of action of platinating agents, our un-
derstanding of genetic variants important in determining
a patient’s likelihood of response or toxicity is extremely
limited. Thus, the development of comprehensive, unbi-
ased models is critical to the identiﬁcation of genetic var-
iants and genes contributing to interindividual variation
in drug effect. Genomewide approaches open up the pos-
sibility of identifying genetic and/or expression signatures
that can be evaluated in clinical trials, for validation.
Previously, we used Epstein-Barr virus (EBV)–trans-
formed B-lymphoblastoid cell lines (LCLs) derived from
healthy individuals within 10 large CEPH pedigrees and
demonstrated that 38%–47% of human variation in sus-
ceptibility to cisplatin-induced cytotoxicity is due to ge-
netic components.14 To better elucidate the genetic vari-
ants important in cisplatin-induced cytotoxicity, we em-
ployed a genomewide association study, using the Inter-
national HapMap cell lines derived from trios of northern
and western European and Yoruban populations. These
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well-genotyped samples provide an extremely rich data
set for genotype–drug effect correlations.15 We performed
gene-expression analysis on these HapMap cell lines, us-
ing the Affymetrix GeneChip Human Exon 1.0 ST Array,
and phenotyped the samples for susceptibility to cis-
platin-induced cytotoxicity. The focus of this article is the
description of genetic variants in two populations that
contribute, through variation in gene expression, to cis-
platin-induced cytotoxicity. To this end, we designed a
three-way model, correlating genotype, gene expression,
and cytotoxicity data, to identify potentially functional
SNPs and/or haplotypes associated with cisplatin-induced
cytotoxicity. Cell lines derived from individuals of Euro-
pean and African descent allow us to deﬁne a set of genetic
variants unique to and common among the populations.
The long-term goal is to identify, through a genetic sig-
nature, patients at risk for adverse events associated with
these agents.
Material and Methods
Material
EBV-transformed LCLs derived from 30 CEPH trios (i.e., mother,
father, and child) collected from Utah residents with northern
and western European ancestry (CEU [HAPMAPPT01]) and from
30 trios collected from Yoruba in Ibadan, Nigeria (YRI [HAP-
MAPPT03]), were purchased from the Coriell Institute forMedical
Research. Cell lines were maintained and were diluted as de-
scribed elsewhere.16 Cisplatin and dimethyl sulfoxide (DMSO)
were purchased from Sigma-Aldrich.
Cytotoxicity Assay
Cell-growth inhibition was evaluated at concentrations of 0,
0.5, 1, 2.5, 5, 10, 20, 40, and 80 mM of cisplatin. Cisplatin was
dissolved in DMSO immediately before use. DMSO concentra-
tions did not exceed 0.1% in the cells. The cytotoxic effect of
cisplatin was determined using the nontoxic colorimetric-based
assay alamarBlue, as described elsewhere.16 The concentration re-
quired to inhibit 50% of cell growth (IC50) was determined by
curve ﬁtting the percentage of cell survival against the concen-
tration of cisplatin.
Genotype and Cytotoxicity Association Analysis
SNP genotypes were downloaded from the InternationalHapMap
database (release 21). To perform a high-quality genomewide as-
sociation study, we employed several data ﬁlters. To reduce pos-
sible genotyping errors, we excluded 100,536 and 138,533 SNPs
with Mendelian allele-transmission errors in 22 autosomes in the
30 CEU and 30 YRI HapMap trios, respectively. To exclude the
extreme outliers and to increase the power of the association
studies within our limited number of samples, we included only
the SNPs that met the criteria of having three genotypes and
containing a minimum of two counts for each genotype in the
unrelated individuals of each population. To obtain functionally
relevant SNPs, we further ﬁltered the SNPs by their location.Only
SNPs located in genes or within 10 kb up- or downstream of a
gene were included. Thus, our ﬁnal data set consisted of 387,417
very informative SNPs covering 22,667 well-annotated genes.
All 175 IC50 values (from 86 CEU and 89 YRI) were log2 trans-
formed to obtain normally distributed data. The quantitative
transmission/disequilibrium test (QTDT) was performed to iden-
tify any genotype-cytotoxicity associations, with the use of QTDT
software.17 Because of the possible heterogeneity between and
within populations, we performed association studies in these
two ethnic groups separately, using sex as a covariate, and to-
gether, using sex and race as covariates. was consideredP  .0001
statistically signiﬁcant.
Gene-Expression Assessment
RNA from 87 CEU and 89 YRI cell lines was extracted after four
dilutions, by use of RNeasy Plus Mini Kits (QIAGEN). RNA quality
was assessed using the RNA 6000 Nano Assay (Agilent Technol-
ogies). For each cell line, ribosomal RNA was depleted from 1 mg
of total RNA by use of the RiboMinus Human/Mouse Transcrip-
tome Isolation Kit (Invitrogen). cDNA was generated using the
GeneChip WT cDNA Synthesis and Ampliﬁcation Kit (Affyme-
trix), per the manufacturer’s instructions. cDNA was fragmented
and end labeled using the GeneChip WT Terminal Labeling Kit
(Affymetrix). Approximately 5.5 mg of labeled DNA target was
hybridized to the Affymetrix GeneChip Human Exon 1.0 STArray
at 45C for 16 h, per the manufacturer’s recommendation (see
Affymetrix Web site for additional information). Hybridized ar-
rays were washed and stained on a GeneChip Fluidics Station 450
and were scanned on a GCS3000 Scanner (Affymetrix). Resulting
probe-signal intensities were sketch-quantile normalized using a
subset of the 1.4 million probe sets. Gene-expression levels were
summarized using the robust multiarray average (RMA). A con-
stant of 16 was added for variance stabilization, and summarized
signals were log2 transformed.
18 This was done with signals gen-
erated on a core set of well-annotated exons (∼200,000) within
the Affymetrix Exon Array Computational Tool (ExACT) software
package. To prevent confounding interpretations of gene-expres-
sion variation, we removed data from exons for which probe sets
contained two or more probes harboring SNPs, before summa-
rizing expression. All raw exon-array data have been deposited
into Gene Expression Omnibus (GEO) (accession number
GSE7761).
Genotype and Gene-Expression Association Analysis
A second QTDT test that integrated mRNA gene expression and
signiﬁcant SNPs found in the genotype and cytotoxicity associ-
ation analysis was performed to identify possible associationwith
gene expression. Signiﬁcant SNPs generated from the genotype-
cytotoxicity association in CEU, YRI, or combined populations
were tested for their association with gene expression in the same
population. Genes with average intensity 15 from Affymetrix
GeneChip Human Exon 1.0 ST Array analysis were considered
expressed and were included in this association analysis. The
QTDT test was performed using gene-expression analysis in CEU
and YRI populations separately and combined, with sex and race
as covariates in the combined samples. We examined not only
the cis-acting gene, deﬁned as gene expression associated with
SNP(s) within 5 Mb on the same chromosome, but also the trans-
acting gene, deﬁned as gene expression associated with SNP(s)
on different chromosome(s) or 15 Mb away on the same chro-
mosome. A Bonferroni correction ( ) that used a number ofP ! .05
transcript clusters in the analysis was used to adjust raw P values
after QTDT analysis.
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Gene Expression and Cisplatin IC50 Linear-Regression
Analysis
To examine the relationship between gene expression and sen-
sitivity to cisplatin, we constructed a general linear model with
log2-transformed cisplatin IC50 as the dependent variable and
RMA-summarized log2-transformed gene-expression level and an
indicator for sex as the independent variables. The dependent
variable was transformed to satisfy the assumption of normality.
Trios were treated as units of analysis, and members of different
families were considered independent. The covariance structure
within a trio was modeled using a Toeplitz structure with two
diagonal bands, such that the trios were ordered father, then
offspring, and then mother. With this covariance structure,
mother and father IC50 values were independent, but the off-
spring’s value was allowed to covary with both the father’s and
mother’s values. If a SNP was signiﬁcantly associated with cis-
platin IC50 and the same SNP was signiﬁcantly associated with
gene expression, then the above approach was used to test
whether gene expression signiﬁcantly predicted IC50. In the CEU
population, 4 transcript clusters were tested for their expression
correlation with cisplatin IC50, whereas 19 transcript clusters were
tested in the YRI population, and 19 transcript clusterswere tested
in the combined CEU and YRI populations. With the combined
approach, predictors of population and sex were included in the
model. Sex was also tested in the separate CEU and YRI popu-
lations as a predictor of cisplatin IC50. was considered sta-P ! .05
tistically signiﬁcant. The model was programmed using the PROC
MIXED procedure in SAS/STAT software version 9.1.19 The RE-
PEATED statement was used to model the Toeplitz covariance
structure. The linkage disequilibrium (LD) of signiﬁcant SNPs
within each population was evaluated using Haploview version
3.32.
Multivariate Model to Predict Association of Cisplatin IC50
with Genotypes
To examine the overall genetic contributions to sensitivity of cis-
platin, additional general linear models were constructed with
transformed cisplatin IC50 as the dependent variable. The inde-
pendent variables included all the signiﬁcant SNP genotypes
(with assumption of an additive genetic effect) that were selected
using the three-way model in the combined populations and in
the two populations independently. These SNP genotypes were
signiﬁcantly associated with cisplatin IC50 through their effect on
gene expression. For the model of combined populations, indi-
cators of race and sex were also included as predictors. Trios were
analyzed as independent units. The covariance was modeled as
described above. Models were reduced using a backward-elimi-
nation approach. SNPs included in each of the ﬁnal models were
statistically signiﬁcant at the level. By use of the ﬁnalap .05
model, predicted transformed IC50 values were computed. For the
unrelated individuals (parents from the trios and, separately, off-
spring from the trios), was estimated between observed IC50
2R
and the predicted IC50 from the ﬁnal model. Lastly, a weighted
average of the two estimates was computed to quantify the2R
amount of variation in cisplatin IC50 explained by the selected
SNP genotypes.
Alternative Methods
Alternative methods were considered to evaluate the endpoints
of the analytical experiments with use of a different initial step
but with the same statistical cutoffs. The ﬁrst alternative approach
involved analyzing the SNP genotype and gene-expression as-
sociation, testing the association of the signiﬁcant SNPs with cis-
platin IC50, and then performing linear regression between gene
expression and cisplatin IC50. The second alternative approach
involved evaluating the correlation between gene expression and
cisplatin IC50, followed by analyzing the SNPs associated with
gene expression and testing the association between those SNPs
and cisplatin IC50.
Results
QTDT Genotype-Cytotoxicity Association
Elsewhere, we reported the median IC50 as 5.1 mM and 6.3
mM for cell lines derived from CEU ( ) and YRInp 86
( ) trios, respectively, after exposure to increasingnp 89
concentrations of cisplatin (0.5–80 mM) for 48 h.16 Inter-
individual variation in the IC50 was 17-fold for CEU and
49-fold for YRI.16 Using 387,417 SNPs representing 22,667
genes (∼85% of genes in the entire genome), we evaluated
whether genetic variation was associated with sensitivity
to cisplatin by use of the IC50 value. An arbitrary P value
threshold ( ) resulted in the identiﬁcation of 96,P .0001
57, and 138 SNPs signiﬁcantly associated with cisplatin
IC50 in the combined, CEU, and YRI populations, respec-
tively (table 1). These SNPs were located in or within 10
kb up- or downstream of 67, 36, and 88 genes, respectively.
QTDT Genotype and Gene-Expression Association
We generated expression data on 176 LCLs (87 CEU and
89 YRI), using the Affymetrix GeneChip Human Exon 1.0
ST Array (an exon array). A total of 14,722 transcript clus-
ters with a mean log2-transformed gene-expression inten-
sity of 15, indicating expression in both CEU and YRI
samples, were included in the analysis. The QTDT asso-
ciation analysis was conducted between gene expression
and the SNPs that were signiﬁcantly associated with cis-
platin IC50. We found 2 cis- and 32 trans-acting relation-
ships in the combined populations, 1 cis- and 3 trans-
acting relationships in CEU, and 2 cis- and 36 trans-acting
relationships in YRI (Bonferroni-corrected ). AmongP ! .05
all observed cis- and trans-acting relationships, some SNPs
were signiﬁcantly associated with more than one gene ex-
pression, and some gene expressions were associated with
more than one SNP. Therefore, the ﬁnal cis- and trans-
acting relationships were represented by 8 SNPs that were
signiﬁcantly associated with 22 gene expressions in the
combined population, by 3 SNPs that were signiﬁcantly
associated with 4 gene expressions in CEU, and by 11 SNPs
that were signiﬁcantly associatedwith 25 gene expressions
in YRI (table 1 and the tab-delimited ASCII ﬁle, which can
be imported into a spreadsheet, of data set 1 [online only]).
Linear Regression of Gene Expression and Cisplatin IC50
We examined the correlation between gene expression
and cisplatin IC50, using a general linear model that was
constructed to reﬂect the trio relationships in our data.
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Table 1. Signiﬁcant Results from the Three-Way Model with Combined, CEU, and YRI
Populations
Approach and Steps
No. of SNPs (No. of Genes)
Combined
Populations CEU YRI
Current:
SNP associated with cisplatin IC50
a 96 (67) 57 (36) 138 (88)
SNP associated with gene expressionb 8 (22) 3 (4) 11 (25)
Gene expression correlated with cisplatin IC50
c 6 (8) 2 (2) 10 (17)
Alternative 1:
SNP associated with gene expressionb 20,440 (8,451) 16,284 (5,922) 23,787 (9,059)
SNP associated with cisplatin IC50
a 8 (22) 3 (4) 11 (25)
Gene expression correlated with cisplatin IC50
c 6 (8) 2 (2) 10 (17)
Alternative 2:
Gene expression correlated with cisplatin IC50
c NA (2,934) NA (1,770) NA (1,882)
SNP associated with gene expressionb 16,129 (2,378) 11,576 (1,311) 21,456 (1,522)
SNP associated with cisplatin IC50
a 22d (19) 8e (8) 36f (24)
NOTE.—NA p not applicable.
a .P  .0001
b Bonferroni-corrected .P ! .05
c .P ! .05
d The additional SNPs generated from this approach are rs10825264, rs10894795, rs12049577, rs12278731,
rs13278343, rs2484665, rs3123678, rs3886003, rs6436716, rs6552924, rs7013683, rs7699288, rs773921,
rs7795668, rs7825213, and rs979532.
e The additional SNPs generated from this approach are rs10898290, rs1556223, rs1953951, rs1975092,
rs2111890, and rs2276607.
f The additional SNPs generated from this approach are rs1004407, rs10053097, rs10221083, rs10431791,
rs12499960, rs1291362, rs17740395, rs1889785, rs2017791, rs4474730, rs6043976, rs6043979, rs6043981,
rs6043984, rs6043986, rs6974263, rs7226876, rs8045919, rs8051159, rs850920, rs940795, rs9455158, rs981890,
rs9821880, rs9881766, and rs9882242.
Since some genes shared the same transcript cluster iden-
tiﬁcation numbers (IDs) on the exon array, the expression
of 19 transcript clusters (representing 22 genes identiﬁed
above) were evaluated in the combined population. Eight
genes had signiﬁcant correlation with cisplatin IC50 (P !
) (table 1). In the same manner, we found 2 and 17.05
genes whose expression signiﬁcantly correlated with cis-
platin IC50 in the CEU and YRI populations, respectively
( ) (table 1, current approach). A summary of SNPsP ! .05
that were found to be signiﬁcantly associated with cispla-
tin IC50 through gene-expression analysis of the CEU, YRI,
and combined populations is shown in table 2.
Alternative methods were considered to evaluate the
endpoints of the analytical experiments with use of a dif-
ferent initial step but with the same statistical cutoff. If
the initial step is the analysis of the SNP genotype and
gene-expression association followed by tests of associa-
tion of the signiﬁcant SNPs with cisplatin IC50 and linear-
regression analysis between gene expression and cisplatin
IC50 (table 1, alternative approach 1), we ﬁnd identical
results. If, however, the initial step is an analysis of gene
expression and cisplatin IC50 followed by analysis of the
SNP associated with gene expression and then association
analysis of those SNPs with cisplatin IC50 (table 1, alter-
native approach 2), the same genetic variants with ad-
ditional variants are identiﬁed. Additional SNPs found
through alternative approach 2 are indicated in table 1.
When the results generated from association tests be-
tween genotype, cisplatin IC50, and gene expression—as
well as the linear-regression results between gene expres-
sion and cisplatin IC50—were combined, we identiﬁed 6,
2, and 10 SNPs that were signiﬁcantly associated with cis-
platin IC50 through regulation of 8, 2, and 17 gene ex-
pressions in the combined, CEU, and YRI populations,
respectively (table 1). One example was the signiﬁcant
association between the genotype of rs456998 (located
within an intron of the FCHSD1 gene on chromosome 5)
and cisplatin IC50 ( ) (ﬁg. 1A). This SNP was
5Pp 4# 10
associated with the expression of DNA-damage–inducible
transcript 4 (DDIT4; on chromosome 10; );6Pp 2# 10
never in mitosis gene A–related kinase 2 (NEK2 [MIM
604043]; on chromosome 1; ); serine hy-6Pp 2# 10
droxymethyltransferase, mitochondrial (SHMT2 [MIM
138450]; on chromosome 12; ); WDR58 (on6Pp 1# 10
chromosome 16; ); and FRAG1 (on chromo-7Pp 2# 10
some 11; ) genes (ﬁg. 1B), whose expression6Pp 3# 10
also signiﬁcantly correlated with cisplatin IC50 in the com-
bined populations ( , , ,4 6 4Pp 1# 10 8# 10 2# 10 7#
, and , respectively) (ﬁg. 1C).4 210 4# 10
In addition, we identiﬁed a signiﬁcant association be-
tween cisplatin IC50 and the genotype of SNP rs8094647
located in the intron of the myosin Vb gene (MYO5B
[MIM 606540]; ) on chromosome 18 (ﬁg. 2A).5Pp 2# 10
This same SNP genotype was signiﬁcantly associated with
the expression of the v-myc avian myelocytomatosis viral
oncogene homolog gene (MYC [MIM 190080]; Pp 1#
) located on chromosome 8 (ﬁg. 2B). TheGGgenotype610
of rs8094647 was associated with higher MYC gene ex-
Table 2. SNPs Associated with Cisplatin IC50 through Gene-Expression Analysis of the CEU, YRI, and Combined Populations
SNP
Host Gene Target Gene P
PopulationChromosome
SNP
Location Name
Transcript Cluster
ID Name
Chromosome
Location
Genotype and
IC50
Genotype and
Expression
Gene Expression and
IC50
rs1649942 10 Intron NRG3 3448088 BHLHB3 12p11.23-p12.1 .00007 .000003 .0038237 CEU
rs7550918 1 Promoter LOC644852 2790062 FLJ32028 4q31.3 .00008 .000003 .0204 CEU
rs4751143 10 Intron EBF3 3867247 DBP 19q13.3 .00006 .0000001 .0342 YRI
rs2305638 3 Intron NBEAL2 2461531 IRF2BP2 1q42.3 .0001 .0000002 .0187 YRI
rs6512670 20 Intron PARD6B 2873785 ALDH7A1 5q31 .00003 .0000003 .0019804 YRI
rs12278731 11 Intron GALNTL4 3705491 FAM57A 17p13.3 .00004 .0000005 .000198 YRI
rs9988868 11 Intron GALNTL4 3705491 FAM57A 17p13.3 .00004 .0000005 .000198 YRI
rs935196 15 Intron ATP8B4 4013434 TAF9L Xq13.1-q21.1 .0001 .0000007 .0008489 YRI
rs12278731 11 Intron GALNTL4 2489228 WDR54 2p13.1 .00004 .000001 .0143 YRI
rs2587708 2 Intron TMEM37 2946319 HIST1H4D 6p21.3 .00004 .000001 .0007479 YRI
rs9988868 11 Intron GALNTL4 2489228 WDR54 2p13.1 .00004 .000001 .0143 YRI
rs11236836 11 Tail LRRC32 3995804 FLJ43855 16p11.2 .0001 .000002 .000005933 YRI
rs11236836 11 Tail LRRC32 3995804 SLC6A8 Xq28 .0001 .000002 .000005933 YRI
rs12278731 11 Intron GALNTL4 2673312 PFKFB4 3p22-p21 .00004 .000003 .0004802 YRI
rs12278731 11 Intron GALNTL4 3622386 GATM 15q21.1 .00004 .000003 .0104 YRI
rs12278731 11 Intron GALNTL4 3965751 HDAC10 22q13.31 .00004 .000003 .00002793 YRI
rs12278731 11 Intron GALNTL4 3965751 MAPK12 22q13.33 .00004 .000003 .00002793 YRI
rs12278731 11 Intron GALNTL4 2339786 KIAA1799 1p31.3 .00004 .000003 .0026355 YRI
rs12278731 11 Intron GALNTL4 2339786 PGM1 1p31 .00004 .000003 .0026355 YRI
rs9988868 11 Intron GALNTL4 3622386 GATM 15q21.1 .00004 .000003 .0104 YRI
rs9988868 11 Intron GALNTL4 2339786 KIAA1799 1p31.3 .00004 .000003 .0026355 YRI
rs9988868 11 Intron GALNTL4 2339786 PGM1 1p31 .00004 .000003 .0026355 YRI
rs9988868 11 Intron GALNTL4 3965751 HDAC10 22q13.31 .00004 .000003 .00002793 YRI
rs9988868 11 Intron GALNTL4 3965751 MAPK12 22q13.33 .00004 .000003 .00002793 YRI
rs9988868 11 Intron GALNTL4 2673312 PFKFB4 3p22-p21 .00004 .000003 .0004802 YRI
rs6537571 10 Promoter C10orf64 2999516 STK17A 7p12-p14 .00007 .000002 .0183372 YRI
rs3732103 2 Intron PQLC3 3761451 HOXB9 17q21.3 .0001 .000003 .00008451 YRI
rs456998 5 Intron FCHSD1 3645565 WDR58 16p13.3 .00004 .0000002 .0006867 Combined
rs173683 5 Intron FCHSD1 3418007 SHMT2 12q12-q14 .0001 .0000006 .0001657 Combined
rs173683 5 Intron FCHSD1 3645565 WDR58 16p13.3 .0001 .0000009 .0006867 Combined
rs8094647 18 Intron MYO5B 3115504 MYC 8q24.12-q24.13 .00002 .000001 .0000000000454 Combined
rs456998 5 Intron FCHSD1 3418007 SHMT2 12q12-q14 .00004 .000001 .0001657 Combined
rs456998 5 Intron FCHSD1 3251393 DDIT4 10pter-q26.12 .00004 .000002 .00009656 Combined
rs456998 5 Intron FCHSD1 2454444 NEK2 1q32.2-q41 .00004 .000002 .000008268 Combined
rs1566347 4 Intron SORBS2 3887117 PPGB 20q13.1 .00006 .000002 .0044 Combined
rs2136241 1 Promoter CDCA1 3850445 CDKN2D 19p13 .00002 .000003 .0157 Combined
rs456998 5 Intron FCHSD1 3317868 FRAG1 11p15.5 .00004 .000003 .0425 Combined
rs7244679 18 Intron MYO5B 3115504 MYC 8q24.12-q24.13 .00005 .000003 .0000000000454 Combined
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Figure 1. Relationship between SNP genotype, gene expression, and cisplatin IC50 in combined CEU and YRI populations. A, Genomewide
association between SNP genotypes and log2-transformed cisplatin IC50 in the combined populations. The X-axis represents the chro-
mosomal location of SNPs. The Y-axis represents the statistical signiﬁcance of association analysis. The dashed line indicates the
signiﬁcance cutoff ( ). B, Association analysis between SNP genotypes and log2-transformed gene expression in the combined
4P 10
populations. The X-axis represents the SNP chromosomal location. The Y-axis represents the statistical signiﬁcance of association
analysis. The dashed line indicates the signiﬁcance cutoff (Bonferroni-corrected ). C, Correlation between log2-transformedP ! .05
cisplatin IC50 and log2-transformed DDIT4, NEK2, SHMT2, WDR58, and FRAG1 expression. All ﬁve gene expressions are signiﬁcantly
associated with one SNP genotype. This SNP, rs456998, is labeled with an asterisk in panels A and B.
pression and lower cisplatin IC50. This was further indi-
cated by the negative correlation found between MYC
gene expression and cisplatin IC50 ( ) (ﬁg. 2C).
11Pp 5# 10
In the individual CEU population, we identiﬁed
rs1649942, located in the intron of the neuregulin 3 gene
(NRG3 [MIM 605533]; ) on chromosome 10,5Pp 7# 10
associated with cisplatin IC50 (ﬁg. 3A) and expression of
basic helix-loop-helix domain–containing protein, class B,
3 gene (BHLHB3 [MIM 606200]; ) (ﬁg. 3B).6Pp 3# 10
We also found a strong correlation between the BHLHB3
expression and cisplatin IC50 ( ) (ﬁg. 3C).
3Pp 4# 10
In the YRI population, we identiﬁed a strong association
between the genotype of SNPs rs12278731 and rs9988868,
both located in the intron of the GALNTL4 gene on chro-
mosome 11, and cisplatin IC50 ( ) (ﬁg. 4A).
5Pp 4# 10
These two SNPs are in complete LD ( ; ). These′ 2D p 1 r p 1
SNP genotypes were also signiﬁcantly associated with the
expression of eight genes: FAM57A (on chromosome 17;
), WDR54 (on chromosome 2; );7 6Pp 5# 10 Pp 1# 10
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4
(PFKFB4 [MIM 605320]; on chromosome 3; Pp 3#
), L-arginine:glycine amidinotransferase (GATM [MIM610
602360]; on chromosome 15; ), histone de-6Pp 3# 10
acetylase 10 (HDAC10 [MIM 608544]; on chromosome
22, ), mitogen-activated protein kinase 126Pp 3# 10
(MAPK12 [MIM 602399]; on chromosome 22; Pp 3#
), KIAA1799 (on chromosome 1; ), and6 610 Pp 3# 10
phosphoglucomutase 1 (PGM1 [MIM 171900]; on chro-
mosome 1; ) (ﬁg. 4B). The CC genotype of6Pp 3# 10
rs12278731 was associated with higher expression of all
eight genes and lower cisplatin IC50. This was further in-
dicated by the inverse correlation found between these
gene expressions and cisplatin IC50 (all ) (ﬁg. 4C).P ! .05
Multivariate Models to Predict Cisplatin IC50 with Genotypes
To examine the overall contributions of our selected ge-
netic variants to sensitivity of cisplatin, we constructed
additional general linear models. All SNP genotypes that
were signiﬁcantly associated with cisplatin IC50 through
their effects on gene expression were included as the in-
dependent variables to predict cisplatin IC50, the depen-
dent variable in each population. The backward-elimi-
nation approach was applied for model reduction. In the
combined population, four of the six tested SNPs were
included in the ﬁnal model ( for all SNPs). Specif-P ! .03
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Figure 2. Relationship between rs8094647, MYC gene expression,
and cisplatin IC50 in combined CEU and YRI populations. A, As-
sociation between rs8094647 genotype and log2-transformed cis-
platin IC50. B, Association between rs8094647 genotype and log2-
transformed MYC expression. C, Correlation of log2-transformedMYC
expression and log2 cisplatin IC50. The number of cell lines per
genotype is labeled directly above the genotype in panels A and
B.
ically, rs1566347, rs2136241, rs456998, and rs7244679
were all signiﬁcant predictors of cisplatin IC50. The indi-
cator of race is not a signiﬁcant predictor of cisplatin IC50
( ). Computing a weighted sum of from each2Pp .13 R
group of unrelated individuals gives an overall estimate
of , which indicates that 27% of the variation in2R p 0.27
cisplatin IC50 can be explained by these four SNPs in the
combined populations. In the CEU population, both
rs1649942 and rs7550918were included in the ﬁnalmodel
( and , respectively). The overall estimatePp .002 Pp .001
of indicates that 29% of the cisplatin IC50 var-
2R p 0.29
iation can be explained by these two SNPs in the CEU
population. In the YRI population, 4 of the 10 tested SNPs
were included in the ﬁnal model ( for all SNPs).P ! .02
Speciﬁcally, rs11236836, rs12278731, rs4751143, and
rs935196 were all signiﬁcant predictors of cisplatin IC50.
The overall estimate of indicates that 45% of2R p 0.45
the cisplatin IC50 variation can be explained by these four
SNPs in the YRI population. The indicator of sex is not a
signiﬁcant predictor of cisplatin IC50 within CEU (Pp
); it is, however, a signiﬁcant predictor ( ) in the.91 Pp .03
YRI population, which agrees with our previous ﬁnding
of a signiﬁcant difference in cisplatin IC50 between female
and male subjects within the YRI population.16
Discussion
Given the wide usage of cisplatin, the high variability of
cisplatin-induced toxicity, and, most importantly, our cur-
rent inability to use genetic variation to identify patients
at risk for toxicity associated with cisplatin, the construc-
tion of a genetic model that provides leads for clinical
testing should signiﬁcantly improve the utility of this
agent. The leads come from a genomewide, unbiased
model that integrates genotype, gene expression, anddrug
sensitivity. This is the ﬁrst attempt to integrate, on a ge-
nomewide scale, SNP-pattern analysis, gene-expression
proﬁling, and a pharmacologic phenotype (cisplatin-in-
duced cytotoxocity) for the discovery of important, novel
genetic information with signiﬁcant clinical potential.We
identiﬁed 17 genetic variants signiﬁcantly associated with
cisplatin-induced cytotoxicity through the expression of
26 genes in cell lines derived from the CEU and/or YRI
populations. These genetic variants can explain ∼27%,
∼29%, and ∼45% of the overall observed cisplatin IC50
variations in the combined, CEU, and YRI populations,
respectively.
Using cell lines derived from large pedigrees, our labo-
ratory was the ﬁrst, to our knowledge, to demonstrate that
a signiﬁcant genetic component contributed to cisplatin
susceptibility.14 More recently, our laboratory has dem-
onstrated that cisplatin-induced cytotoxicity is a highly
heritable trait, with 34% of the variation in IC50 for 324
LCLs (derived from 27 large CEPH pedigrees) due to ge-
netic factors ( ) (S. Shukla, S. Duan, J. Badner,7Pp 1# 10
X. Wu, and M. E. Dolan, unpublished data). Linkage anal-
ysis revealed suggestive and signiﬁcant LOD scores 12 at
two chromosomal regions. Since no signiﬁcantpopulation
differences in cisplatin-induced cytotoxicity were ob-
served between the CEU and YRI populations, we com-
pared the linkage-scan results obtained from the large
CEPH pedigrees with the present association ﬁndings.16
Among all signiﬁcant SNPs that were found to be asso-
ciated with cisplatin IC50 through gene-expression anal-
ysis, two of them are also under suggestive linkage peaks
(11p15.4-15.1; LOD 12). These SNPs, rs12278731 and
rs9988868, are in complete LD ( ; ), are located′ 2D p 1 r p 1
within the intron regions of GALNTL4 on chromosome
11, and are signiﬁcantly associated with the expression of
eight genes (FAM57A, WDR54, PFKFB4, GATM, HDAC10,
MAPK12, KIAA1799, and PGM1) in the YRI population.
The different allele frequencies of the SNPs ( )F p 0.14ST
between the CEU and YRI populations may account for
the signiﬁcant association observed in YRI but not in CEU
when our current approach was used.
In the current study, we evaluated the HapMap trios, of
which extensive genotypic information provided reason-
able power to detect genetic variants that were signiﬁ-
cantly associated with drug sensitivity. LCLs derived from
two HapMap populations, CEU and YRI, were evaluated
together and separately to detect signiﬁcant genetic var-
iants that contribute to cell sensitivity to cisplatin in each
population and in both populations combined. Given the
stringent statistical cutoffs, we did not observe any overlap
of SNPs between the CEU and YRI populations. This was
not surprising, given the heterogeneity between the CEU
and YRI samples. Nor did we observe SNPs that overlapped
between the combined populations and the individual
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Figure 3. Relationship between SNP genotype, gene expression, and cisplatin IC50 in CEU population. A, Genomewide association
between SNP genotypes and log2-transformed cisplatin IC50 in CEU population. The X-axis represents the chromosomal location of SNPs.
The Y-axis represents the statistical signiﬁcance of association analysis. The dashed line indicates the signiﬁcance cutoff ( ).4P 10
B, Association analysis between SNP genotypes and log2-transformed gene expression in CEU population. The X-axis represents the SNP
chromosomal location. The Y-axis represents the statistical signiﬁcance of association analysis. The dashed line indicates the signiﬁcance
cutoff (Bonferroni-corrected ). C, Correlation between log2-transformed cisplatin IC50 and log2-transformed BHLHB3 expression.P ! .05
SNP rs1649942, which is signiﬁcantly associated with cisplatin IC50 and BHLHB3 expression, is labeled with an asterisk in panels A and
B.
populations. The larger number of samples in the com-
bined populations provides more power to detect smaller
genetic effects on cytotoxicity and gene expression. How-
ever, by combining the CEU and YRI data, the unique
genetic ﬁndings in one population may be masked by the
noise produced by the lack of a genetic effect in the other
population. Thus, we interpreted the ﬁnal results in each
separate population as population-speciﬁc genetic vari-
ants that contribute to cisplatin toxicity, whereas those in
the combined population are genetic variants important
to drug-induced toxicity, regardless of population tested.
Furthermore, our three-step model links genotype, gene
expression, and sensitivity to cisplatin, to decrease the
potential false-discovery rate. A genomewide association
test between genotype and cisplatin IC50 yielded 96, 57,
and 138 signiﬁcant SNPs ( ) associated with cis-P .0001
platin IC50 from the combined and CEU- and YRI-derived
cell lines, respectively. All these could be functionally im-
portant; however, the consideration of a subgroup of those
that act through gene expression narrows the list to 6, 2,
and 10 SNPs signiﬁcantly associated with the expression
of 8, 2, and 17 genes and signiﬁcantly correlated with
cisplatin IC50 ( ) in combined, CEU, and YRI popu-P ! .05
lations, respectively. Our long-term goal is to identify, be-
fore chemotherapy, patients who are at risk for toxicity.
Since genotyping is clinically more practical than gene-
expressionmeasurements, each approach considered (cur-
rent and alternatives 1 and 2) results in a genetic signature
that considers SNPs that are important in cytotoxicity and
expression. The ﬁrst alternative approach is also a SNP-
oriented approach and produced exactly the same results
as our current approach. The second alternative approach
focused on correlating gene expression with cytotoxicity,
then ﬁnding SNPs associated with those genes, and eval-
uating the ﬁnal SNPs with cytotoxicity. For SNP and gene-
expression association, all approaches used Bonferroni
correction with the number of transcript clusters in that
particular analysis. Since the second alternative approach
had fewer transcript clusters in the denominator (only
gene expression that was signiﬁcantly correlated with cis-
platin IC50), the P value cutoff was less stringent and re-
sulted in a higher number of SNPs.
Although all 26 genes should be considered important,
there are a number of genes with considerable evidence
in the literature—for example, DDIT4, NEK2, and MYC.
DDIT4 is a known mediator of reactive-oxygen species
generation.20 The role of DDIT4 in cell sensitivity to cis-
platin has been suggested in the Affymetrix Human HG-
U133A chip analysis in NT2/D1 (human embryonal car-
cinoma) cell lines after cisplatin treatment, with up-
regulation of DDIT4 gene expression after cisplatin treat-
ment coincident with a 60% decrease in cell viability.21
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Figure 4. Relationship between SNP genotype, gene expression, and cisplatin IC50 in YRI population. A, Genomewide association
between SNP genotypes and log2-transformed cisplatin IC50 in YRI population. The X-axis represents the chromosomal location of SNPs.
The Y-axis represents the statistical signiﬁcance of association analysis. The dashed line indicates the signiﬁcance cutoff ( ).4P 10
B, Association analysis between SNP genotypes and log2-transformed gene expression in YRI population. The X-axis represents the SNP
chromosomal location. The Y-axis represents the statisticial signiﬁcance of association analysis. The dashed line indicates the signiﬁcance
cutoff (Bonferroni-corrected ). C, Correlation between log2-transformed cisplatin IC50 and log2-transformed FAM57A, WDR54,P ! .05
PFKFB4, GATM, HDAC10, MAPK12, KIAA1799, and PGM1 expression. HDAC10 and MAPK12 share the same transcript cluster ID on exon
array, as do KIAA1799 and PGM1. All six transcript clusters are signiﬁcantly associated with one SNP genotype. This SNP, rs12278731,
is labeled with an asterisk in panels A and B.
Furthermore, the higher DDIT4 gene expression was also
observed in the SQ20b (head and neck cancer) cell line
after treatment with O6-benzylguanine plus cisplatin,
compared with cisplatin alone. This higher gene expres-
sion was concomitant with higher cisplatin-induced cy-
totoxicity, further suggesting that higher DDIT4 expres-
sion level may lead to enhanced sensitivity to cisplatin.22
Our study showed that the TT genotype of SNP rs456998
was associated with higher DDIT4 gene expression and
higher sensitivity to cisplatin, in agreement with literature
evidence.22 Given the evidence of inducibility of this gene
by cisplatin, we are currently evaluatingDDIT4 expression
changes over time after treatment.
NEK2, another gene whose expression is strongly as-
sociated with the rs456998 genotype, is required for the
correct execution of mitosis.23 Zhang et al. have shown
that irradiation-induced DNA damage leads to inhibition
of Plk1, which leads to subsequent inhibition of Nek2
activity and thus prevents centrosome separation in HeLa
and U2OS cell lines.24 The depletion of Nek2 leads to an
apparent arrest in Hela cell proliferation and an increase
in apoptosis, possibly as a result of mitotic errors.25,26 Our
current study showed that the TT genotype of SNP
rs456998 was associated with higher NEK2 gene expres-
sion and higher sensitivity to cisplatin. Using the Affy-
metrix U133A microarray, we found that Nek2 expression
patterns were signiﬁcantly different between cisplatin-
sensitive and cisplatin-resistant LCLs after 8 h of cisplatin
treatment (S. Duan,W. Bleibel, C. Cheng, andM. E. Dolan,
unpublished data).
Another interesting ﬁnding is the signiﬁcant association
of the genotype of SNP rs8094647 with cisplatin IC50
( ), as well as with the expression of the MYC5Pp 2# 10
gene ( ). The protein encoded by MYC is a6Pp 1# 10
multifunctional, nuclear phosphoprotein that plays a role
in cell-cycle progression, apoptosis, and cellular transfor-
mation. It functions as a transcription factor that regulates
transcription of speciﬁc target genes. Pretreatment with
10058-F4, a small-molecule c-Myc inhibitor, increased the
chemosensitivity of HepG2 (hepatocellular carcinoma)
cells to low-dose doxorubicin, 5-ﬂuorouracil, and cispla-
tin.27 We found that the GG genotype of rs8094647 was
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associated with higher MYC gene expression and lower
cisplatin IC50. Because it has been shown that cisplatin
treatment down-regulates MYC gene expression at both
the mRNA level (in NT2/D1 cells)21 and protein level (in
Hela cervical carcinoma cells),28 we are currently investi-
gating the relationship between sensitivity to cisplatin,
SNP genotype, and MYC gene expression after cisplatin
treatment.
Because of the relatively small sizes of HapMap samples,
our approach focused on SNPs within or close to gene
regions with fairly high allele frequencies, to increase the
power to detect signiﬁcant genetic variants associated
with the cytotoxicity. Furthermore, the multivariatemod-
el used to test association between multiple SNPs and IC50
demonstrated the power of our approach. With a limited
number of SNP genotypes (four, two, and four SNPs in the
combined, CEU, and YRI populations, respectively), we
were able to predict 27%, 29%, and 45% of the cisplatin
IC50 variation in these LCLs. Although the full implica-
tions and biological signiﬁcance of other genes and net-
works identiﬁed through our approach are not yet com-
pletely understood, these studies will likely help to direct
clinical studies by providing a strong list of candidate
genes on which to focus. They may serve as a platform
for the further exploration of relevant mechanisms and
may improve our understanding of the molecular basis of
cisplatin-induced cytotoxicity. We are currently validating
these ﬁndings in a set of unrelated CEPH cell lines.
One potential limitation of these cell lines is that EBV
transformation could have an effect on drug sensitivity
and/or expression proﬁles. Therefore, the model could
miss some genes of importance because either they are
not expressed in these cell lines or, upon transformation,
the genes are down-regulated. Another important caveat
of the model is the use of gene-expression analysis to nar-
row the number of associated genetic variants. The po-
tential to miss genetic variants that affect cytotoxicity
through effects on protein structure, activity, and/or deg-
radation exists. However, the association test between cis-
platin IC50 and genotype (current approach, ﬁrst step) is
inclusive of all genetic variants that act through these
means (see the tab-delimited ASCII ﬁle of data set 1 [on-
line only]). Furthermore, the dense genotyping within
HapMap cell lines allows systematic, genomewide asso-
ciation analysis that would not be possible in other sys-
tems. We recognize that there likely are expression and
posttranslational-modiﬁcation differences in various tis-
sues. Of the 26 genes we identiﬁed in LCLs, 18 were also
expressed in human kidney tissue, which is one of the
major sites of cisplatin-induced toxicity (GeneCards Web
site). The genetic variants that are associatedwith cisplatin
cytotoxicity within genes in human kidney are decent
candidates to evaluate with patients that experience ne-
phrotoxicity. Furthermore, the model can be applied to
uncover the genetic signatures contributing to a wide
range of cellular phenotypes.
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